NEW YORK (GenomeWeb News) – The Cambridge, UK-based translational genomics company Horizon Discovery announced today that it has signed a non-exclusive commercial agreement with OSI Pharmaceuticals. Under the agreement, OSI will evaluate nine of Horizon’s X-MAN cell lines and matched cells with normal genetic backgrounds for 12 months, starting this month.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.